Figure 4 | Scientific Reports

Figure 4

From: Immunogenicity and Protection Against Influenza H7N3 in Mice by Modified Vaccinia Virus Ankara Vectors Expressing Influenza Virus Hemagglutinin or Neuraminidase

Figure 4

Immunogenicity and protective effectiveness of MVA-HA or MVA-NA. Groups of mice (5 per group) were vaccinated with 107 PFU of recombinant MVA-HA or MVA-NA vectors. A control group was vaccinated with 107 PFU of MVA. After 3 weeks, sera were collected from mice and tested for H7-specific IgG in an antigen capture ELISA, using purified recombinant H7 protein (a). NA-specific IgG was assayed using purified recombinant N3 protein or purified recombinant N9 protein (b). Data show the individual IgG titers. The horizontal bar indicates the mean IgG titer and error bars represent standard deviation. All mice were challenged 3 weeks post-vaccination with 10 LD50s of influenza A/mallard/Netherlands/12/2000 (H7N3) via the intranasal route. Weight loss is shown in (c), with the number of surviving mice in each group indicated in parentheses. Survival curves for the different treatment groups are shown in (d).

Back to article page